Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.

doi:10.1373/clinchem.2014.230235

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.

Clinical chemistry - 1 Jan 2015

Sanmamed Miguel F, Fernández-Landázuri Sara, Rodríguez Carmen, Zárate Ruth, Lozano María D, Zubiri Leyre, Perez-Gracia José Luis, Martín-Algarra Salvador, González Alvaro

Abstract excerpt

BACKGROUND: Around 50% of cutaneous melanomas harbor the BRAF(V600E) mutation and can be treated with BRAF inhibitors. DNA carrying this mutation can be released into circulation as cell-free BRAF(V600E) (cfBRAF(V600E)). Droplet digital PCR (ddPCR) is an analytically sensitive technique for quant...

Topics

Antineoplastic Agents
DNA
DNA Mutational Analysis
Disease-Free Survival
Female
Follow-Up Studies
Humans
Imidazoles
Indoles
Kaplan-Meier Estimate
Male

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Melanoma

Middle Aged

Mutation

Oximes

Polymerase Chain Reaction

Proto-Oncogene Proteins B-raf

Sulfonamides

Source

Open in PubMed

Identifiers

PMID: 25411185
DOI: 10.1373/clinchem.2014.230235

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-25411185-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.PMID 25411185Read ↗

Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR.Semantic proximity Read ↗

Clinical validation and implementation of droplet digital PCR for the detection of BRAF mutations from cell-free DNA.Semantic proximity Read ↗

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.Semantic proximity Read ↗

BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.Semantic proximity Read ↗

Microarray-based analysis of the BRAF V600 mutations in circulating tumor DNA in melanoma patients.Semantic proximity Read ↗

Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.Semantic proximity Read ↗

Liquid biopsy-based analysis by ddPCR and CAPP-Seq in melanoma patients.Semantic proximity Read ↗

Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene PanelSemantic proximity Read ↗

Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients.Semantic proximity Read ↗

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.Semantic proximity Read ↗

Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.Semantic proximity Read ↗

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.